Managing new-onset heart failure (HF) is a delicate task for cardiologists, and one that demands an appropriate balance between aggressive treatment and optimal quality of life for the patient. But that balance may be harder to strike…

Istaroxime, a dual action, luso-inotropic agent that’s still in clinical development, was granted fast-track designation by the FDA this month as a possible treatment for acute heart failure with reduced ejection fraction (HFrEF).…

The FDA on August 16 granted breakthrough designation to CVRx Inc.’s Barostim Neo System, a device meant to improve heart failure symptoms in patients unsuited for other therapies like CRT. 

The Barostim Neo is…

Biopharmaceutical company Renovacor, Inc., on August 14 announced it had raised $11 million in Series A financing to further develop its gene therapy-based treatments for CVD.

Renovacor, which is based in Philadelphia, locked…

Swiss drugmaker Novartis on July 29 announced its combo sacubitril/valsartan drug Entresto “narrowly missed” its primary endpoint in the Phase III PARAGON-HF study, throwing into question the future of a blockbuster drug.

Basel-…

A study published July 17 in the Journal of the American College of Cardiology has revealed a strong link between cancer and takotsubo cardiomyopathy, or “…

Methamphetamine abuse (MA) is on the rise among veterans with concomitant heart failure (HF), according to a recent analysis published in the American…

Researchers in Italy are developing “smart,” photo-responsive materials they hope will replicate the mechanical properties of a human heart in an artificial format, Cosmos Magazine reported July 12.

Camilla Parmeggiani…

Despite our best efforts to treat the underlying heart disease, people living with advanced cardiovascular disease experience considerable suffering. Heart failure comes with a heavy symptom burden, a complex and unpredictable disease trajectory…

The combination heart failure drug sacubitril/valsartan is well-covered under Medicare Part D plans, according to a recent analysis, but patient access to the medication remains limited by steep out-of-pocket costs than can exceed $1,…

A large-scale study of people living with HIV has linked the immune deficiency to an increased risk of CVD, in particular heart failure and stroke.

The research, published this month in the…

Heart patients of a lower socioeconomic status are far more likely to participate in cardiac rehabilitation if they receive financial incentives to attend sessions, according to a study published in the July 1 edition of…

The FDA on June 26 granted Boehringer Ingelheim and Eli Lilly and Company’s drug empagliflozin Fast Track designation for the treatment of chronic heart failure, the companies announced.

Empagliflozin, marketed by U.S…

One in five Americans are able to recognize the symptoms of heart failure, according to a new survey from Abbott—a troublesome finding considering the same research puts the average individual just four degrees of separation from HF.…

Researchers at Imperial College London have developed a sew-on heart patch that leverages stem cells to support and repair heart muscle after a heart attack—something that could dramatically lower MI survivors’ risk of future heart…

Less than 10% of heart failure (HF) patients comply with physicians’ advice on salt and fluid restrictions, daily weigh-ins and physical activity, according to research presented at this year’s European Society of Cardiology Heart…

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF)…

The risk of peripartum cardiomyopathy (PPCM) is up to five times higher in mothers who undergo common fertility treatments like intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF), according to data presented at…

Results from the FDA’s latest investigation into Abiomed’s Impella RP system are in—and, with a couple of caveats, they’re positive.

The Impella right ventricular assist device—a temporary right heart pump system that…

A six-week online training course centered around living with an implantable cardioverter-defibrillator (ICD) helped alleviate anxiety in heart failure patients who were apprehensive about their devices.

Study head…

The Heart Rhythm Society issued a first-ever…